WASHINGTON, Jan. 24, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science
The finalists will now go to Washington, D.C. from March 9-15 to undergo a rigorous judging process to determine the top 10 winners. They will also have the opportunity to meet with national leaders and share their projects with the public at the National Geographic Society. This year's finalists will compete for more than $1.8 million in top awards – more than half of the Regeneron Science Talent Search total annual award distribution of $3.1 million. The top 10 awards range from $40,000 to $250,000 for the first place winner. Winners will be announced at a formal awards gala at the National Building Museum on March 14.
"Regeneron is proud to recognize the top 40 Regeneron Science Talent Search finalists. These talented young scientists are already exploring life-changing solutions for the world's problems and are poised to lead innovation for future generations," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron. "I've had the opportunity to meet many of my fellow Science Talent Search alumni who have gone on to become notable scientists and entrepreneurs, underscoring the critical role the program can play in launching a prominent scientific career."
"These 40 young scientists, engineers and mathematicians are poised to be the next generation of leaders in business and academia," said Maya Ajmera, president and CEO of Society for Science & the Public and publisher of Science News. "Science breeds curiosity, enabling innovators to develop solutions that will help solve our world's most pressing challenges. We are proud to celebrate 75 years of recognizing new innovations and research demonstrating the outstanding capabilities of young minds." The Society for Science & the Public has produced and organized the Science Talent Search since it was founded in 1942.
Regeneron Science Talent Search 2017 Fast Facts
About the Regeneron Science Talent SearchThe Regeneron Science Talent Search, a program of Society for Science & the Public since 1942, is the nation's oldest and most prestigious science and math competition for high school seniors. Each year, approximately 1,700 student entrants to the Science Talent Search submit original research in critically important scientific fields of study and are judged by leading experts in their fields. Unique among high school competitions in the U.S. and globally, the Regeneron Science Talent Search focuses on identifying the next generation of scientists and engineers who will provide critical leadership in solving some of the world's most pressing challenges while shaping the future of research and development for our nation and the world.
As part of its 10-year, $100 million commitment, Regeneron has significantly increased awards to better reward the best and brightest young talent and encourage their continued pursuit of scientific innovation. Regeneron has nearly doubled the overall award distribution to $3.1 million annually, increased the top award to $250,000.
Program alumni include recipients of the world's most coveted science and math honors, including eleven National Medals of Science, four Breakthrough Prizes, eighteen MacArthur Foundation Fellowships, two Fields Medals and twelve Nobel Prizes. Distinguished Science Talent Search alumni include Society Trustees Mary Sue Coleman (president emeritus, University of Michigan), Tom Leighton (co-founder and CEO, Akamai Technologies), Paul Maddon (founder of Progenics) and Frank Wilczek (2004 Nobel Prize in Physics), among many others.
Intel was the title sponsor of the Science Talent Search from 1998-2016. For the first 55 years (1942-1997) of the Science Talent Search, Westinghouse was the title sponsor.
Learn more at https://student.societyforscience.org/regeneron-sts and https://medium.com/regeneron-science-talent-search.
About Society for Science & the PublicSociety for Science & the Public is dedicated to the achievement of young scientists in independent research and to public engagement in science. Established in 1921, Society is a nonprofit whose vision is to promote the understanding and appreciation of science and the vital role it plays in human advancement. Through its world-class competitions, including the Regeneron Science Talent Search, the Intel International Science and Engineering Fair, and the Broadcom MASTERS, and its award-winning magazine, Science News and Science News for Students, Society for Science & the Public is committed to inform, educate, and inspire. Learn more at www.societyforscience.org and follow us on Facebook, Twitter, Instagram and Snapchat (Society4Science).
About Regeneron Pharmaceuticals, Inc.Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, atopic dermatitis, asthma, pain, cancer and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Media Contact at Society for Science & the PublicGayle KansagorPhone: 703-489-1131Email: email@example.com
Media Contact at Regeneron Hala MirzaPhone: 914-847-3422E-Mail: Hala.Mirza@regeneron.com
Media Contact at North of Nine CommunicationsOlivia CampbellPhone: 212-614-4831Email: Olivia.Campbell@nof9.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/forty-of-nations-brightest-young-scientists-named-regeneron-science-talent-search-2017-finalists-300395479.html
SOURCE Regeneron Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All